- Home
- NPCT vs ITOS Comparison
NPCT vs ITOS Comparison
Compare NPCT & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- ITOS
- Stock Information
- Founded
- NPCT 2020
- ITOS 2011
- Country
- NPCT United States
- ITOS United States
- Employees
- NPCT N/A
- ITOS N/A
- Industry
- NPCT Investment Managers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPCT Finance
- ITOS Health Care
- Exchange
- NPCT Nasdaq
- ITOS Nasdaq
- Market Cap
- NPCT 306.8M
- ITOS 270.7M
- IPO Year
- NPCT N/A
- ITOS 2020
- Fundamental
- Price
- NPCT $10.96
- ITOS $10.04
- Analyst Decision
- NPCT
- ITOS Hold
- Analyst Count
- NPCT 0
- ITOS 6
- Target Price
- NPCT N/A
- ITOS $10.60
- AVG Volume (30 Days)
- NPCT 107.1K
- ITOS 1.8M
- Earning Date
- NPCT 01-01-0001
- ITOS 08-07-2025
- Dividend Yield
- NPCT 9.82%
- ITOS N/A
- EPS Growth
- NPCT N/A
- ITOS N/A
- EPS
- NPCT N/A
- ITOS N/A
- Revenue
- NPCT N/A
- ITOS $35,000,000.00
- Revenue This Year
- NPCT N/A
- ITOS N/A
- Revenue Next Year
- NPCT N/A
- ITOS N/A
- P/E Ratio
- NPCT N/A
- ITOS N/A
- Revenue Growth
- NPCT N/A
- ITOS 177.89
- 52 Week Low
- NPCT $8.58
- ITOS $4.80
- 52 Week High
- NPCT $10.63
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- NPCT 67.73
- ITOS 65.62
- Support Level
- NPCT $10.55
- ITOS $9.91
- Resistance Level
- NPCT $10.75
- ITOS $10.20
- Average True Range (ATR)
- NPCT 0.11
- ITOS 0.16
- MACD
- NPCT 0.01
- ITOS -0.11
- Stochastic Oscillator
- NPCT 95.35
- ITOS 32.50
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.